The global ingredient manufacturer Döhler has begun commercial production in Europe of Superbrewed Food's postbiotic protein, SB1.
SB1 is a fermentation-derived Postbiotic Cultured Protein—a whole-food protein ingredient that delivers high-quality protein alongside meaningful levels of naturally occurring B-vitamins and essential minerals, enabling structure/function claims in finished products.
The protein ingredient is also allergen-free, non-GMO and vegan, supporting clean-label, nutrient-dense formulations across nutrition and food applications.
The ingredient had received a GRAS ('no questions' letter) from the FDA in 2024 and, according to Superbrewed, has attracted interest across applications such as protein beverages and snacks.
The launch occurs during a significant shift in dietary preferences, marked by a greater emphasis on reducing sugar intake and on protein-rich nutrition.
This change has been influenced by GLP-1 medications and broader wellness trends that are reshaping consumer habits.
Superbrewed's platform converts sugar into SB1, meeting the growing demand for premium ingredients that deliver more than just isolated proteins.
"Establishing commercial production with Döhler is a defining step for Superbrewed," said Bryan Tracy, CEO of Superbrewed Food.
Döhler's global manufacturing platform and commercialisation capabilities position SB1 to scale efficiently and meet accelerating demand for high-quality protein.
Döhler Ventures also made an undisclosed strategic investment in Superbrewed, which the company says reinforced its long-term commitment to fermentation-enabled nutrition and the global expansion of SB1.
"Superbrewed's SB1 represents a differentiated innovation in the evolving protein landscape," said Rodrigo Hortega de Velasco, Managing Partner at Döhler Ventures.
Through commercial manufacturing and strategic investment, we are committed to supporting SB1 as it scales globally.
This milestone marks Superbrewed's transition from development to the first phase of commercial production.
SB1 is being manufactured at a Döhler European production facility, leveraging Döhler's global scale, quality systems and ingredient expertise.
Initial commercial volumes are now shipping into premium sports and lifestyle nutrition applications in the US.
The companies plan to expand production capacity and advance broader commercialisation together in 2027.